RMIT scientists in Melbourne have led an international collaboration that potentially unlocks better treatment of viral diseases, including the flu and common cold.
The results were published in the prestigious scientific and medical journal Nature Communications.
Each year the flu virus sends 13,500 Australians to hospital and causes more than 3000 deaths among those aged over 50. The global burden is also staggering, with more than 5 million cases of infection annually with up to 10 per cent resulting in death.
The RMIT senior authors, Dr Stavros Selemidis (ARC Future Fellow) and Dr Eunice To (first author), collaborated with Professor Doug Brooks from University South Australia, Professor John O’Leary from Trinity College Dublin, Monash University’s Professor Christopher Porter, and other scientists and clinicians to investigate how viruses cause disease in humans.
The researchers discovered that a 1.5 billion-year-old cell biological process found in plants, fungi and mammals enhances viral disease in mice and highly likely also in humans. They identified a protein, Nox2 oxidase, that is activated by viruses, including influenza, rhinovirus (the common cold), dengue and HIV.
Once activated, Nox2 oxidase suppresses the body’s key antiviral reaction and its ability to fight and clear the viral infection, which in turn results in a stronger or more virulent disease in mice.
The study also investigated a new prototype drug to treat these debilitating viral diseases.
The researchers found that the Nox2 oxidase protein activated by the viruses is located in a cell compartment called endosomes. They carefully modified a chemical that inhibits or restrains the activity of Nox2 oxidase.
Their customised drug was found to be very effective at suppressing disease caused by influenza infection.
Selemidis, head of the Oxidant and Inflammation Biology Group within the Chronic Infectious and Inflammatory Diseases program at RMIT, said: “Current treatment strategies are limited as they specifically target circulating viruses and have either unknown or very little effect against new viruses that enter the human population.
“We have identified a protein of the immune system that contributes to the disease caused by flu viruses irrespective of their strain.
“We also developed a novel drug delivery system to target this protein, which drastically alleviated the burden of viral disease.
“The strength of this work is the multidisciplinary approach taken and the degree of collaboration. It includes researchers and clinicians from eight universities across Australia, the United States and Ireland.
“This work attracted considerable interest at the NADPH Oxidase GORDON conference in the USA last year.”
To said: “This work identifies a treatment strategy that has the potential to alleviate the symptoms caused by some of the most devastating viruses worldwide, including the flu.”
The Latest on: Viral diseases
- Laboratory Studies Confirm BETADINE(R) Antiseptic Products' Effectiveness Against COVID-19 Viruson July 9, 2020 at 4:04 pm
Mundipharma today announced that laboratory testing at the Duke-NUS Medical School in Singapore, has confirmed the effectiveness of ...
- Laboratory Studies Confirm BETADINE® Antiseptic Products’ Effectiveness Against COVID-19 Viruson July 9, 2020 at 3:50 pm
Mundipharma today announced that laboratory testing at the Duke-NUS Medical School in Singapore, has confirmed the effectiveness of its BETADINE® antiseptic products against the novel coronavirus ...
- Where do new viruses like the coronavirus come from?on July 9, 2020 at 3:36 pm
Factors smaller than a cell and as large as the planet are at play when a virus leaps from an animal to a human. The question of how that happened with SARS-CoV-2, which causes the disease COVID-19, ...
- State now reporting 150,450 virus caseson July 9, 2020 at 3:12 pm
The number of new coronavirus cases reported by the state Thursday was more than 1,000 for the first time in more than a month. This comes as health officials warn of increases in cases, especially ...
- Trump Administration May Use Infectious-Disease Risk As Reason To Deny Asylum To More Immigrantson July 9, 2020 at 6:10 am
A proposed rule would allow federal agencies to block people from countries with widespread communicable disease from seeking ... epidemic sweeps the U.S. The virus has killed more than 130,000 ...
- Global Infectious Diseases Market 2020 analysis with Key Players, Applications, Trends and Forecasts by 2025on July 9, 2020 at 2:59 am
Our Other report : Global Flavonoids Market 2020 Share, Growth by Top Company, Region, Application, Driver, Trends and Forecasts by 2024 Global Renal Disease Treatment Devices Market 2020 analysis ...
- IDEAL, the Infectious Diseases of East African Livestock project open access database and biobankon July 9, 2020 at 2:06 am
Health • disease • genotype • Phenotypic variability Technology Type(s) Examination • single-nucleotide polymorphism analysis Sample Characteristic - Organism Bos indicus Sample Characteristic - Envir ...
- 8 Questions From a Disease Detective on the Pandemic’s Originson July 8, 2020 at 8:47 pm
Dr. Daniel R. Lucey wants answers to pointed questions that bear on how the coronavirus leapt from bats to humans.
- Infectious Disease Treatment Market Size to surpass 5.1%+ CAGR up to 2025on July 8, 2020 at 2:34 pm
Selbyville, Delaware Market Study Report, LLC’s latest addition on ‘ Infectious Disease Treatment market’ is a research that features comprehensive outlook pertaining to market valuations, market ...
- Infectious diseases experts cautions U.S. could see death rate riseon July 8, 2020 at 4:05 am
Dr. Paul Sax, Clinical Director of Infectious Diseases at Brigham and Women's Hospital, discusses virus infections, why he says the U.S. death rate could rise and he also discusses improvements in ...
via Google News and Bing News